Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

Area of Science:

• Oncology
• Cancer Evolution
• Pharmacology

Background:

• Current cancer therapy often treats drug resistance after relapse.
• Tumor clonal evolution and associated fitness costs may create exploitable vulnerabilities.
• This study introduces the concept of "temporal collateral sensitivity."

Purpose of the Study:

• To investigate temporal collateral sensitivity in cancer drug resistance.
• To explore vulnerabilities arising during the evolution of resistance to BCR-ABL1 inhibitors.
• To identify novel therapeutic strategies targeting dynamic tumor vulnerabilities.

Main Methods:

• Utilized a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).
• Employed a combined pharmacological screen and drug resistance selection approach.
• Integrated genotypic, phenotypic, signaling, and binding measurements with computational modeling.

Main Results:

• Discovered temporal and persistent collateral sensitivity to non-classical BCR-ABL1 drugs in resistant Ph(+) ALL subpopulations.
• Demonstrated significant overall survival extension in treated mice.
• Identified the sensitization mechanisms through comprehensive analyses.

Conclusions:

• Temporal collateral sensitivity represents a promising therapeutic vulnerability in evolving cancers.
• Focusing on evolutionary trajectories and drug pharmacological profiles can reveal new treatment strategies.
• This approach holds potential for treating dynamic tumor vulnerabilities in hematological malignancies.